Power3’s Goldknopf Presents at International Molecular Diagnostic Meeting in Beijing 12/01/2009 PWRM

Posted on 12/1/2009 10:48:17 AM in #Stocks | 0 comments comments

_______________________________________

FREE Daily Stock Alerts From CRWEWallStreet.com

_______________________________________

Power3’s Goldknopf Presents at International Molecular Diagnostic Meeting in Beijing

- President, Chief Scientific Officer Keynotes and Chairs Session on November 20, 2009, Meets with Leading Biotech Company, Explores Development and Launch of Diagnostic Tests in Chinese Market -

HOUSTON–(CRWENEWSWIRE) Dec/1/2009. Power3 Medical Products, Inc. (OTCBB: PWRM), a leader in neurodegenerative disease and cancer biomarkers and diagnostic tests reports that the company’s President and CSO, Dr. Ira Goldknopf, delivered an invited Keynote address and chaired a session on “Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting was “New Leadership of Personalized Medicine.” .

Dr. Goldknopf described the company’s unique ability to employ Power3’s blood protein biomarkers to differentially diagnose mild Alzheimer’s and Parkinson’s diseases, distinguish between them, distinguish from normal controls, distinguish from patients with Alzheimer’s and Parkinson’s like disorders (disease controls) and distinguish drug naïve and drug treated patients. He also presented results for early diagnosis of invasive breast cancer with and without ductal carcinoma in situ, distinguishing between them, distinguishing them from normal and benign controls. The final topic covered was the discovery of biomarkers in bone marrow cells from chronic myelogenous leukemia patients that predict whether they would respond to the drug imatinib mesylate (Gleevec).

“Power3 has begun confidential discussions with a flagship Chinese Biotechnology Company with an eye to co-develop high throughput blood tests for the Chinese market,” said Dr Goldknopf. “We intend to establish a major worldwide presence.”

“We are extremely proud and excited about the interest generated by Dr. Goldknopf’s presentation of our results at this international meeting,” said Ms. Helen Park, Power3’s CEO, “particularly the new findings in clinical validation of the company’s biomarkers and unique blood tests and the continuing discussions leading to their commercialization in China.”

About Power3 Medical Products, Inc.:

Power3 Medical Products (OTCBB:PWRM) (http://www.Power3Medical.com) is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro®) and breast cancer (BC-SeraPro™). Power3 expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer’s disease (NuroPro-AD), Parkinson’s disease (NuroPro-PD) and breast cancer in 2010, followed by filings with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, and breast cancer.

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.

Contact:

Investor Relations

Crown Equity Holdings, Inc.

Kenneth Bosket, CEO/President

(877) 854-6797 toll-free

(702) 448-1543 office

Cautionary Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management’s current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release.

Source: Power3 Medical

************Advertisement************

************************************

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty four thousand dollars from Tax Masters Inc. (TAXS.OB) for 30 days of advertisement services. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB)